Warrior Met Coal, Inc. HCC
83.50 USD -1.95 (-2.28%)
At closeNov 11, 2026, 5:25 PM EST
83.50 0.00 0.00%
After hours · Nov 11, 5:25 PM ET
83.30 Day range 86.00
71.80 52-week range 111.42
- YTD
- -5.30%
- 1 year
- +1.26%
News
marketbeat.com Warrior Met Coal Q3 Earnings Call Highlights Warrior Met Coal NYSE: HCC reported higher third-quarter revenue and profit as increased production from its Blue Creek mine and stronger steelmaking coal prices helped generate $139 million in free…
benzinga.com UBS Maintains Buy on Warrior Met Coal, Lowers Price Target to $97 UBS analyst George Eadie maintains Warrior Met Coal (NYSE:HCC) with a Buy and lowers the price target from $102 to $97.
seekingalpha.com Warrior Met Coal, Inc. (HCC) Q3 2026 Earnings Call Transcript Warrior Met Coal, Inc. ( HCC ) Q3 2026 Earnings Call November 4, 2026 4:30 PM EST Company Participants Brian M. Chopin - Senior VP, Chief Accounting Officer & Controller Walter Scheller - CEO &…
zacks.com Warrior Met Coal (HCC) Lags Q3 Earnings Estimates Warrior Met Coal (HCC) came out with quarterly earnings of $0.93 per share, missing the Zacks Consensus Estimate of $1.71 per share. This compares to earnings of $0.7 per share a year ago.
benzinga.com Warrior Met Coal Q3 2026 Earnings Call Transcript Warrior Met Coal (NYSE:HCC) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to…
businesswire.com Warrior Reports Third Quarter 2026 Results BROOKWOOD, Ala.--(BUSINESS WIRE)--Warrior Met Coal, Inc. (NYSE: HCC) (“Warrior” or the “Company”) today announced results for the third quarter of 2026. Warrior is the leading dedicated U.S.-based…
seekingalpha.com Dividend Announcements: October 24-30, 2026 (Part 2 Of 2) I monitor dividend increases and cuts across 1,200+ stocks, focusing on dividend growth streaks, safety, and valuation to identify high-conviction opportunities. STX stands out with the highest…
benzinga.com Warrior Met Coal Declares Special Dividend Of $2 Per Share Warrior Met Coal, Inc. (NYSE:HCC) ("Warrior" or the "Company") today announced that its board of directors has declared a special cash dividend of $2.00 per share to be paid on November 20, 2026, to
businesswire.com Warrior Met Coal Declares Special Cash Dividend BROOKWOOD, Ala.--(BUSINESS WIRE)--Warrior Met Coal, Inc. (NYSE:HCC) (“Warrior” or the “Company”) today announced that its board of directors has declared a special cash dividend of $2.00 per share to…
zacks.com Warrior Met Coal (HCC) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Warrior Met Coal (HCC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
businesswire.com Warrior Announces Regular Quarterly Cash Dividend BROOKWOOD, Ala.--(BUSINESS WIRE)--Warrior Met Coal, Inc. (NYSE:HCC) (“Warrior” or the “Company”) today announced that its board of directors has approved a regular quarterly cash dividend of $0.08…
benzinga.com B. Riley Securities Maintains Buy on Warrior Met Coal, Lowers Price Target to $122 B. Riley Securities analyst Nick Giles maintains Warrior Met Coal (NYSE:HCC) with a Buy and lowers the price target from $123 to $122.
gurufocus.com Sonesitatug vedotin reduced the risk of death by 42% in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers in CLARITY-Gastric01 Positive results from the CLARITY-Gastric01 global Phase III trial showed AstraZeneca's sonesitatug vedotin (Sone-Ve) demonstrated a statistically significant a
gurufocus.com IMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial Landmark results from the DeLLphi-305 Phase III trial showed IMFINZIÂ (durvalumab) plus Amgen's tarlatamab-dlle demonstrated a statistically significant and hi
gurufocus.com Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer Positive results from the VOLGA Phase III trial showed perioperative treatment with AstraZeneca's IMFINZIÂ (durvalumab) in combination with neoadjuvant enfortu
gurufocus.com BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026 [url="]BeOne Medicines Ltd.[/url] (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated inve
gurufocus.com Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (NASDAQ: MRNA) today announced detailed positive recurrence-free surv
businesswire.com Warrior Sets Date for Third Quarter 2026 Earnings Announcement and Investor Conference Call BROOKWOOD, Ala.--(BUSINESS WIRE)--Warrior Met Coal, Inc. (“Warrior” or NYSE: HCC) today announced that it will hold its third quarter 2026 investor conference call at 4:30 p.m. ET on Wednesday,…
seekingalpha.com Black Bear Value Partners Q3 2026 - Top 5 Businesses We Own Black Bear Value Fund, LP (the “Fund”) returned -10.3% in September, +2.5% in the quarter and +4.1% YTD. Builders FirstSource declined approximately 36% during the third quarter and was down roughly…
seekingalpha.com Warrior Met Coal: A Volume Story Still Priced Like A Coal Price Bet Warrior Met Coal now drives earnings growth through volume and cost reductions, not just coking coal price leverage. Blue Creek Mine's early ramp added a second product line, boosting Q2 sales to a…
247wallst.com Warren Buffett's Succession Triggers Search for His Spiritual Successors Warren Buffett's step back from Berkshire forces a harder question: which public companies actually run his playbook, and how close do any of them get to the real thing?
gurufocus.com Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC) Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency's Committee for Medicinal Products for Hu
benzinga.com RBC Capital Maintains Sector Perform on Warrior Met Coal, Raises Price Target to $110 RBC Capital analyst Sam Crittenden maintains Warrior Met Coal (NYSE:HCC) with a Sector Perform and raises the price target from $90 to $110.
defenseworld.net Jupiter Topco LLC Takes $1.83 Million Position in Warrior Met Coal $HCC Jupiter Topco LLC acquired a new stake in Warrior Met Coal (NYSE: HCC) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 22,560 shares of the…
benzinga.com Here’s How Much You Would Have Made Owning Warrior Met Coal Stock In The Last 5 Years Warrior Met Coal (NYSE:HCC) has outperformed the market over the past 5 years by 22.59% on an annualized basis producing an average annual return of 33.71%. Currently, Warrior Met Coal has a market…
benzinga.com Top 3 Materials Stocks That Could Sink Your Portfolio This Month As of Sept. 1, 2026, three stocks in the materials sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
benzinga.com Top 3 Materials Stocks That Could Sink Your Portfolio This Month As of Sept. 1, 2026, three stocks in the materials sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum…- benzinga.com Here’s How Much You Would Have Made Owning Warrior Met Coal Stock In The Last 5 Years Warrior Met Coal (NYSE:HCC) has outperformed the market over the past 5 years by 25.76% on an annualized basis producing an average annual return of 37.05%. Currently, Warrior Met Coal has a market…
- benzinga.com UBS Maintains Buy on Warrior Met Coal, Lowers Price Target to $98 UBS analyst George Eadie maintains Warrior Met Coal (NYSE:HCC) with a Buy and lowers the price target from $100 to $98.
benzinga.com Warrior Met Coal Q2 EPS $1.65 Beats $1.55 Estimate, Sales $509.690M Beat $488.358M Estimate Warrior Met Coal (NYSE:HCC) reported quarterly earnings of $1.65 per share which beat the analyst consensus estimate of $1.55 by 6.45 percent. This is a 1400 percent increase over earnings of $0.11…- benzinga.com UBS Maintains Buy on Warrior Met Coal, Lowers Price Target to $100 UBS analyst George Eadie maintains Warrior Met Coal (NYSE:HCC) with a Buy and lowers the price target from $102 to $100.
benzinga.com B. Riley Securities Maintains Buy on Warrior Met Coal, Raises Price Target to $123 B. Riley Securities analyst Nick Giles maintains Warrior Met Coal (NYSE:HCC) with a Buy and raises the price target from $117 to $123.
benzinga.com UBS Maintains Buy on Warrior Met Coal, Lowers Price Target to $102 UBS analyst George Eadie maintains Warrior Met Coal (NYSE:HCC) with a Buy and lowers the price target from $104 to $102.
benzinga.com Warrior Met Coal Q1 2026 Earnings Call: Complete Transcript - benzinga.com Warrior Met Coal Q1 EPS $1.37 Beats $1.16 Estimate, Sales $458.588M Miss $465.987M Estimate Warrior Met Coal (NYSE:HCC) reported quarterly earnings of $1.37 per share which beat the analyst consensus estimate of $1.16 by 18.1 percent. This is a 956.25 percent increase over losses of $(0.16)…
benzinga.com Earnings Scheduled For April 30, 2026 - benzinga.com White House Says President Trump Signs Memo Related To Coal Supply Chains https://www.whitehouse.gov/presidential-actions/2026/04/presidential-determination-pursuant-to-section-303-of-the-defense-production-act-of-1950-as-amended-on-coal-supply-chains-and-baseload-power-gen…
- benzinga.com UBS Maintains Buy on Warrior Met Coal, Raises Price Target to $105 UBS analyst George Eadie maintains Warrior Met Coal (NYSE:HCC) with a Buy and raises the price target from $101 to $105.
- benzinga.com Citigroup Maintains Buy on Warrior Met Coal, Raises Price Target to $100 Citigroup analyst Alexander Hacking maintains Warrior Met Coal (NYSE:HCC) with a Buy and raises the price target from $80 to $100.
- benzinga.com UBS Maintains Buy on Warrior Met Coal, Raises Price Target to $101 UBS analyst George Eadie maintains Warrior Met Coal (NYSE:HCC) with a Buy and raises the price target from $100 to $101.
- benzinga.com B. Riley Securities Maintains Buy on Warrior Met Coal, Raises Price Target to $120 B. Riley Securities analyst Nick Giles maintains Warrior Met Coal (NYSE:HCC) with a Buy and raises the price target from $117 to $120.
benzinga.com Warrior Met Coal Q4 Earnings Report: What Investors Need to Know - benzinga.com Warrior Met Coal Q4 EPS $0.44 Misses $0.50 Estimate, Sales $383.988M Beat $379.194M Estimate Warrior Met Coal (NYSE:HCC) reported quarterly earnings of $0.44 per share which missed the analyst consensus estimate of $0.50 by 11.47 percent. This is a 193.33 percent increase over earnings of…
- benzinga.com Earnings Scheduled For February 12, 2026
benzinga.com Trump Orders Pentagon To Buy 'Lot Of' Coal Power, Pledges $175 Million For Plant Upgrades— Coal Stocks Shine In Thursday Pre-Market (UPDATED) President Donald Trump signed an executive order on Wednesday directing the Department of War to buy electricity from coal-fired power plants, aiming to support the struggling coal industry.
benzinga.com Earnings Outlook For Warrior Met Coal - benzinga.com UBS Upgrades Warrior Met Coal to Buy, Raises Price Target to $108 UBS analyst George Eadie upgrades Warrior Met Coal (NYSE:HCC) from Neutral to Buy and raises the price target from $100 to $108.
- benzinga.com Expert Outlook: Warrior Met Coal Through The Eyes Of 5 Analysts
benzinga.com The Coal Peak Is Now, IEA Study Shows Coal demand to reach record high in 2025, then decline due to renewables, nuclear, and natural gas. China's consumption to peak by 2030.
benzinga.com Is the Market Bullish or Bearish on Warrior Met Coal Inc?